Related references
Note: Only part of the references are listed.Precancerous lesions of the pancreas
Giuseppe Zamboni et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2013)
MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress
Qiongqiong Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma
David V. Gold et al.
CANCER (2013)
The Epidemiology of Pancreatitis and Pancreatic Cancer
Dhiraj Yadav et al.
GASTROENTEROLOGY (2013)
Current concepts and novel targets in advanced pancreatic cancer
Patrick Michl et al.
GUT (2013)
Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions
Antonio Gnoni et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin
David V. Gold et al.
MOLECULAR CANCER (2013)
Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration
Sandra Cascio et al.
ONCOTARGET (2013)
MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes
S. Nath et al.
ONCOGENESIS (2013)
Fractionated Radioimmunotherapy With 90Y-Clivatuzumab Tetraxetan and Low-Dose Gemcitabine Is Active in Advanced Pancreatic Cancer
Allyson J. Ocean et al.
CANCER (2012)
Multimodality Imaging of Pancreatic Cancer-Computed Tomography, Magnetic Resonance Imaging, and Positron Emission Tomography
Siva P. Raman et al.
CANCER JOURNAL (2012)
MUC1 Contributes to BPDE-Induced Human Bronchial Epithelial Cell Transformation through Facilitating EGFR Activation
Xiuling Xu et al.
PLOS ONE (2012)
Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
Seza A. Gulec et al.
CLINICAL CANCER RESEARCH (2011)
Detection of Early-Stage Pancreatic Adenocarcinoma
David V. Gold et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Noninvasive Radiofrequency Field Destruction of Pancreatic Adenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles
Evan S. Glazer et al.
CLINICAL CANCER RESEARCH (2010)
Pretargeted Radioimmunotherapy of Pancreatic Cancer Xenografts: TF10-90Y-IMP-288 Alone and Combined with Gemcitabine
Habibe Karacay et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Epidemiology of pancreatic cancer: an overview
Sara Raimondi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2009)
MRI for malignant pancreatic tumors
J. Gaa et al.
RADIOLOGE (2009)
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma
David V. Gold et al.
CANCER RESEARCH (2008)
PAW-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma
David V. Gold et al.
CLINICAL CANCER RESEARCH (2007)
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis
DV Gold et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Combined 90yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft
DV Gold et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Improved targeting of pancreatic cancer: Experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy
TM Cardillo et al.
CLINICAL CANCER RESEARCH (2004)
Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
TM Cardillo et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4
DV Gold et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
Share Paper
